Key highlights
- FDA grants seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl)
- Market exclusivity period is retroactive to the initial approval date of February 3, 2025
- Supplemental New Drug Application submitted for a secondary manufacturing supplier
- Potential FDA approval for the second supplier is anticipated by mid-year 2027
- ONAPGO is the first subcutaneous apomorphine infusion device for advanced Parkinson’s motor fluctuations
What Approval Was Received?
The U.S. Food and Drug Administration (FDA) has officially recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl). This regulatory milestone applies to the treatment of motor fluctuations in adult patients diagnosed with advanced Parkinson’s disease. The exclusivity period is valid through early 2032, as it was backdated to the medication's initial approval on February 3, 2025. The designation is part of the FDA's program to support the development of therapies for conditions affecting fewer than 200,000 individuals in the United States annually.
Down 30.0% since our story on 22 Oct: $41.21 when we broke it → $28.83 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $33.87 |
|---|---|
| 20 Oct | $34.77 |
| 21 Oct | $34.79 |
| 22 Oct | $35.33 |
| 23 Oct | $34.47 |
| 26 Oct | $34.56 |
| 27 Oct | $34.72 |
| 28 Oct | $34.77 |
| 29 Oct | $35.25 |
| 30 Oct | $35.37 |
| 2 Nov | $36.28 |
| 3 Nov | $28.15 |
| 4 Nov | $28.21 |
| 5 Nov | $26.74 |
| 6 Nov | $26.16 |
| 9 Nov | $27.62 |
| 10 Nov | $28.75 |
| 11 Nov | $29.45 |
| 12 Nov | $29.20 |
| 13 Nov | $29.72 |
| 16 Nov | $28.83 |
Why This Approval Matters
Obtaining orphan-drug exclusivity provides a significant competitive moat by preventing the FDA from approving the same drug for the same indication for seven years. This protection is critical for Supernus as it scales ONAPGO, which remains the only subcutaneous apomorphine infusion device on the market. By securing this status, the company protects its intellectual property and market share against generic entries during the primary growth phase of the product. This development follows the company's successful effort in 2026 to clear a supply backlog of over 700 patients.
Path to Market
Beyond the exclusivity win, Supernus is actively diversifying its production capabilities to prevent future supply disruptions. The company has filed a supplemental New Drug Application (sNDA) for a second supplier, aiming for regulatory clearance by mid-2027. This move is designed to ensure an uninterrupted drug supply for the advanced Parkinson’s community. The expansion of the supply chain coincides with the company’s broader strategic shifts, including a pending merger of equals with Indivior Pharmaceuticals, which is scheduled to close on November 2, 2026.
Business Overview
Supernus Pharmaceuticals is a biopharmaceutical firm specializing in central nervous system (CNS) disorders. Its commercial portfolio includes treatments for ADHD, epilepsy, migraine, and Parkinson’s disease, featuring brands like Qelbree and Gocovri. For the full year 2026, management raised total revenue guidance to a range between $860 million and $890 million. The company maintains a strong focus on neuroscience, with an R&D pipeline targeting chronic sialorrhea and cervical dystonia. The upcoming third-quarter financial results are scheduled for release on October 29, 2026.
| Date | Announcement | Amount |
|---|---|---|
| 21 Oct 2026 | Supplemental New Drug Application (sNDA) submitted to the FDA for a second manufacturing supplier for ONAPGOSource: ir.supernus.com | – |
| 21 Oct 2026 | FDA recognized 7 years of orphan-drug market exclusivity for ONAPGO (apomorphine HCl)Source: ir.supernus.com | – |
| 04 Feb 2025 | FDA approval of ONAPGO (apomorphine hydrochloride) infusion device for Parkinson's diseaseSource: ir.supernus.com | – |
| 27 Jan 2025 | FDA approval of expanded label update for Qelbree (viloxazine) adding pharmacodynamic and lactation dataSource: ir.supernus.com | – |
Management commentary
“Securing orphan-drug exclusivity marks an important milestone for individuals and families navigating Parkinson's disease. This designation validates the urgent need for targeted therapies and helps safeguard continued innovation in a long-underserved community.”
“In addition to resolving the supply issue from earlier this year, submitting our sNDA further reinforces our ongoing commitment to providing novel treatments for patients with Parkinson's disease, backed by our unwavering focus on ensuring an uninterrupted drug supply for every patient in need.”
| Share price | $41.21 |
|---|---|
| Market cap | $2.4B |
| Revenue (annual) | $719M |
| 1-month price change | -3.67% |
| Sector | HealthcareDrug Manufacturers - Specialty & Generic |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Supernus Pharmaceuticals, Inc. announcing FDA orphan-drug exclusivity recognition and a supplemental New Drug Application.
Track SUPERNUS PHARMACEUTICALS, INC. live
Get the next SUPERNUS PHARMACEUTICALS, INC. SEC filing seconds after it lands.



